Article Text

PDF
Review: corticosteroids plus LABAs reduce exacerbations and mortality more than steroids alone in COPD

Statistics from Altmetric.com

Dr L J Nannini

Correspondence to: Dr L J Nannini, Hospital G Baigorria, Rosario, Argentina; nanninilj@cimero.org.ar

QUESTION

In patients with stable chronic obstructive pulmonary disease (COPD), how do inhaled corticosteroids (ICSs) combined with long-acting β-agonists (LABAs) compare with ICSs alone?

REVIEW SCOPE:

Studies selected had ⩾2 weeks’ duration and compared combination therapy of ICSs plus LABAs with ICSs alone in patients >45 years of age with stable COPD and no exacerbation for 1 month before study entry, including those with partial reversibility on pulmonary function testing. Studies of patients who had asthma, bronchiectasis, cystic fibrosis, or other lung diseases were excluded. Outcomes were exacerbations, mortality, and pneumonia. Secondary outcomes included lung function (FEV1), quality of life (St …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.